Skip to main content

Labcorp company profile

  • LH · NYSE
  • Healthcare
  • Health Care Services
  • S&P 500
$370.48−0.49%Close 13 Nov 2026 · Market value $30.04B

About Labcorp

Labcorp Holdings Inc. provides laboratory services that supply information to doctors, hospitals, pharmaceutical companies, researchers, and patients. It operates two segments: Dx, which offers routine and specialty clinical testing through primary and specialty laboratories in the U.S. and Canada, and BLS, which provides drug development services including central laboratory, safety assessment, and clinical trial sample management to pharmaceutical and biotechnology companies. Dx also serves physicians, health systems, health plans, and consumers, with patient service centers across the U.S. The company reports that its operations span approximately 100 countries, with employees located in 17 countries.

A summary of the business section of the company's latest annual report, filed 24 Feb 2026.

Company facts

TickerLH · NYSE
SectorHealthcare
IndustryHealth Care Services
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK920148
Latest annual report10-K, filed 24 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
ADAM H. SCHECHTERPresident & CEO · Director397K · < 1%Sale under a 10b5-1 plan, 11 Aug 2026
BRIAN J. CAVENEYEVP, Pres of ED, CMO & CSO74.1K · < 1%Grant or award, 26 Mar 2026
MARK S. SCHROEDEREVP, Pres Diagnostics & COO57.0K · < 1%Shares withheld for tax, 26 Mar 2026
PETER M. NEUPERTDirector13.8K · < 1%Option exercise, 11 Feb 2026
GARHENG KONGDirector13.7K · < 1%Option exercise, 11 Feb 2026
KERRII B. ANDERSONDirector9.9K · < 1%Sale under a 10b5-1 plan, 17 Aug 2026
JULIA A. WANGChief Financial Officer, EVP9.8K · < 1%Option exercise, 11 Feb 2026
MEGAN D. BAILEYEVP, Pres, Central Labs & Intl7.9K · < 1%Shares withheld for tax, 26 Mar 2026
JEFFREY A. DAVISDirector5.5K · < 1%Option exercise, 11 Feb 2026
KATHRYN E. WENGELDirector4.1K · < 1%Option exercise, 11 Feb 2026
RICHELLE P. PARHAMDirector3.4K · < 1%Option exercise, 11 Feb 2026
KIRSTEN M. KLIPHOUSEDirector3.2K · < 1%Option exercise, 11 Feb 2026
PAUL B. ROTHMANDirector2.6K · < 1%Option exercise, 11 Feb 2026
Summy Amy B.EVP, Chief Marketing Officer—Open-market sale, 4 Aug 2026
Wilkinson Peter JSVP, Chief Accounting Officer—Open-market sale, 3 Aug 2026
Kyle Kathryn WEVP, Chief Legal Officer—Sale under a 10b5-1 plan, 2 Jul 2026
Vaughn Bryan TEVP and President, Diagnostics—Sale under a 10b5-1 plan, 2 Jul 2026
Meltzer Jonathan CEVP, Operations—Sale under a 10b5-1 plan, 27 Mar 2026
GRAHAM ANITA ZEVP, CHRO—Grant or award, 26 Mar 2026
van der Vaart Sandra DEVP, Corporate Affairs—Grant or award, 26 Mar 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

LH in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.